Medication Summary
Mesalamine
Brand names: Apriso, Canasa, Delzicol, Lialda, Pentasa
Dosage form: Delayed Release Capsule
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
DELZICOL is an aminosalicylate indicated for: Treatment of mildly to moderately active ulcerative colitis in patients 12 years of age and older (1.1) Maintenance of remission of ulcerative colitis in adults (1.2)
What should I know before taking it?
DELZICOL is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of DELZICOL [see Warnings and Precautions (5.3), Adverse Reactions (6.2), and Description (11)].
What important warnings are listed?
Renal Impairment (for example, minimal change nephropathy, acute and chronic interstitial nephritis, renal failure): Assess renal function at beginning of treatment and periodically during treatment (5.1) Mesalamine-induced Acute Intolerance Syndrome: Has been reported. Observe patients closely for worsening of these symptoms while on treatment (5.2) Hypersensitivity Reactions: Use caution when treating patients who are hypersensitive to sulfasalazine. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported (5.3) Hepatic Failure: Has been reported in patients with pre-existing liver disease. Use caution when treating patients with liver.
How is this medication usually taken?
DELZICOL (mesalamine) delayed-release capsules are red capsules containing 400 mg mesalamine and imprinted with “WC 400mg” in white.
What side effects are listed?
The most serious adverse reactions seen in DELZICOL clinical trials or with other products that contain or are metabolized to mesalamine are: Renal impairment, including renal failure [see Warnings and Precautions (5.1)] Acute intolerance syndrome [see Warnings and Precautions (5.2)] Hypersensitivity reactions [see Warnings and Precautions (5.3)] Hepatic failure [see Warnings and Precautions (5.4)] The data presented in Section 6.1 are from clinical trials conducted with mesalamine delayed-release tablets. DELZICOL is bioequivalent to these mesalamine delayed-release tablets.
What interactions are listed?
No formal drug interaction studies have been performed using DELZICOL with other drugs. However, the following interactions between mesalamine-containing products and other drugs have been reported.
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.